{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:55:13Z","timestamp":1791078913919,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin lymphomas (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents approximately 60% of all CTCL, followed by S\u00e9zary syndrome (SS), approximately 5%. We retrospectively analyzed the outcome of 118 patients with MF (n=96) and SS (n=22) treated between the years 1998 and 2021 at the Charles University General Hospital in Prague, Czech Republic. The ratio between men and women was 1.2:1 (62 men, and 56 women). The median age at diagnosis was 62 years (23 to 92 years). From the MF cohort 48 patients (50% out of MF cohort) presented with advanced stage disease. Ninety patients (77%) received a systemic treatment at any time from the diagnosis; the median number of therapy lines was two. At the time of database lock, the overall survival (OS) of 96 patients with MF reached 17.7 years with the median follow-up 4.0 years. With the median follow-up 2.6 years, the median OS of 22 patients with SS was 3.5 years. The most common type of systemic therapy for MF included low-dose methotrexate (61%), interferon-alpha (58%), bexarotene (28%), and chlorambucil (25%). The most common type of therapy for SS included bexarotene (64%), extracorporeal photopheresis (50%), and interferon-alpha (45%). Only the minority of patients received innovative targeted agents including brentuximab vedotin, mogamulizumab, or pembrolizumab. Besides the retrospective analysis of the CTCL cohort, current standards and future perspectives of selected innovative agents are summarized and discussed. The analyzed cohort represents the largest cohort of CTCL patients in the Czech Republic. Overall, the survival parameters of our CTCL cohort are comparable to those previously published by other groups. In conclusion, our analysis of 118 real world cohort of consecutive CTCL patients treated at the single center confirmed the efficacy of immune response modifiers and underlines the urgent need for ample implementation of innovative agents and their combinations into earlier lines of therapy.<\/jats:p>","DOI":"10.3389\/fonc.2022.884091","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:26:12Z","timestamp":1654593972000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience"],"prefix":"10.3389","volume":"12","author":[{"given":"Kamila","family":"Polg\u00e1rov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Pol\u00edvka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Kodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 Update of the WHO-EORTC Classification for Primary Cutaneous Lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"B2","volume-title":"Epidemiology of Primary Cutaneous Lymphomas in the Czech Republic According to Data of the Czech National Cancer Registry","author":"Polivka","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing Incidence Trends of Cutaneous T-Cell Lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival Outcomes and Prognostic Factors in Mycosis Fungoides\/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer Staging Proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A Cutaneous Lymphoma International Prognostic Index (CLIPi) for Mycosis Fungoides and Sezary Syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14559","article-title":"The New Cutaneous Lymphoma International Prognostic Index (CLIPi) for Early Mycosis Fungoides Failed to Identify Prognostic Groups in a Cohort of Spanish Patients","volume":"175","author":"Sanz-Bueno","year":"2016","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15000","article-title":"Prognostic Indicators for Mycosis Fungoides in a Greek Population","volume":"176","author":"Nikolaou","year":"2017","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jid.2019.07.712","article-title":"Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-Analysis","volume":"140","author":"Mourad","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T Cell Lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer Consensus Recommendations for the Treatment of Mycosis Fungoides\/Sezary Syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary Cutaneous Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines for the Management of Primary Cutaneous Lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14657","article-title":"Low-Dose Total Skin Electron Beam Therapy Plus Oral Bexarotene Maintenance Therapy for Cutaneous T-Cell Lymphoma","volume":"20","author":"Elsayad","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","unstructured":"Primary Cutaneous Lymphoma2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab Vedotin or Physician's Choice in CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA): An International, Open-Label, Randomised, Phase 3, Multicentre Trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to Brentuximab Vedotin Versus Physician's Choice by CD30 Expression and Large Cell Transformation Status in Patients With Mycosis Fungoides: An ALCANZA Sub-Analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized Phase 3 ALCANZA Study of Brentuximab Vedotin vs Physician's Choice in Cutaneous T-Cell Lymphoma: Final Data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab Versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC): An International, Open-Label, Randomised, Controlled Phase 3 Trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17523","article-title":"Efficacy and Safety of Mogamulizumab by Patient Baseline Blood Tumour Burden: A Post Hoc Analysis of the MAVORIC Trial","volume":"35","author":"Cowan","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1953007","article-title":"Lack of Impact of Type and Extent of Prior Therapy on Outcomes of Mogamulizumab Therapy in Patients With Cutaneous T Cell Lymphoma in the MAVORIC Trial","volume":"62","author":"Horwitz","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S0959-8049(21)00659-6","article-title":"Understanding Relative Survival Outcomes for Patients With Cutaneous T-Cell Lymphoma (CTCL) Subtypes Mycosis Fungoides and S\u00e9zary Syndrome Treated With Mogamulizumab or Vorinostat: Combining Australian Real-World Evidence and MAVORIC Phase 3 Trial Data","volume":"156","author":"Rem\u00e1k","year":"2021","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000263","article-title":"What Factors Guide Treatment Selection in Mycosis Fungoides and Sezary Syndrome","volume":"2021","author":"Kim","year":"2021","journal-title":"Hematology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11864-021-00899-0","article-title":"How to Sequence Therapies in Mycosis Fungoides","volume":"22","author":"Brumfiel","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the Staging and Classification of Mycosis Fungoides and Sezary Syndrome: A Proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.08.004","article-title":"Mycosis Fungoides","volume":"65","author":"Zinzani","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-Term Outcome of 525 Patients With Mycosis Fungoides and Sezary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.027","article-title":"Advanced-Stage Mycosis Fungoides and S\u00e9zary Syndrome: Survival and Response to Treatment","volume":"15","author":"Alberti-Violetti","year":"2015","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in Cutaneous T-Cell Lymphoma by Skin Stage: Long-Term Survival in 489 Patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.025","article-title":"Quality of Life in Patients With Mycosis Fungoides and Sezary Syndrome Undergoing Low-Dose Total Skin Electron Beam Therapy With or Without Maintenance Therapy","volume":"86","author":"Nawar","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/S0959-8049(21)00681-X","article-title":"An Update on Health-Related Quality of Life From the PROCLIPI Study","volume":"156","author":"Molloy","year":"2021","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of Durable Disease Control With Chemotherapy for Mycosis Fungoides and Sezary Syndrome: A Comparative Study of Systemic Therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a First-in-Class Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma: An International, First-in-Human, Open-Label, Phase 1 Trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(21)00664-X","article-title":"Lacutamab in Patients (Pts) With Advanced Mycosis Fungoides (MF) According to KIR3DL2 Expression: Early Results From the TELLOMAK Phase 2 Trial","volume":"156","author":"Bagot","year":"2021","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146115","article-title":"The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides\/Sezary Syndrome Alone or With Doxorubicin","volume":"11","author":"Moyal","year":"2016","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-Delta,Gamma Inhibitor Duvelisib in a Phase 1 Trial and Preclinical Models of T-Cell Lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an Open-Label Multicenter Phase 2 Trial of Lenalidomide Monotherapy in Refractory Mycosis Fungoides and Sezary Syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24895","article-title":"A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas","volume":"92","author":"Boonstra","year":"2017","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/hon.56_2879","article-title":"The Combination Of Duvelisib And Romidepsin (Dr) Is Highly Active Against Relapsed\/Refractory Peripheral T-Cell Lymphoma With Low Rates Of Transaminitis: Final Results","volume":"39","author":"Horwitz","year":"2021","journal-title":"Hematological Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.07.053","article-title":"Novel Cell Adhesion\/Migration Pathways are Predictive Markers of HDAC Inhibitor Resistance in Cutaneous T Cell Lymphoma","volume":"46","author":"Andrews","year":"2019","journal-title":"EBioMedicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663961","article-title":"Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/cco.2018.11.02","article-title":"Sezary Syndrome, Recent Biomarkers and New Drugs","volume":"8","author":"Cristofoletti","year":"2019","journal-title":"Chin Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.884091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:26:18Z","timestamp":1654593978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.884091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":47,"alternative-id":["10.3389\/fonc.2022.884091"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.884091","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"article-number":"884091"}}